These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37566530)

  • 1. Telemedicine Use, Comfort, and Perceived Effectiveness in the Spinal Muscular Atrophy Community.
    Peterson IS; Belter LT; Curry MA; Jarecki J
    Telemed J E Health; 2024 Feb; 30(2):536-544. PubMed ID: 37566530
    [No Abstract]   [Full Text] [Related]  

  • 2. Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the Cure SMA Community Update Survey.
    Belter L; Cruz R; Jarecki J
    Orphanet J Rare Dis; 2020 Aug; 15(1):217. PubMed ID: 32838797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy.
    Pacione M; Siskind CE; Day JW; Tabor HK
    J Neuromuscul Dis; 2019; 6(1):119-131. PubMed ID: 30594933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating Benefit-risk Decision-making in Spinal Muscular Atrophy: A First-ever Study to Assess Risk Tolerance in the SMA Patient Community.
    Cruz R; Belter L; Wasnock M; Nazarelli A; Jarecki J
    Clin Ther; 2019 May; 41(5):943-960.e4. PubMed ID: 31056304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cure SMA Membership Surveys: Highlights of Key Demographic and Clinical Characteristics of Individuals with Spinal Muscular Atrophy.
    Belter L; Jarecki J; Reyna SP; Cruz R; Jones CC; Schroth M; O'Toole CM; O'Brien S; Hall SA; Johnson NB; Paradis AD
    J Neuromuscul Dis; 2021; 8(1):109-123. PubMed ID: 33104036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cure SMA Clinical Trial Experience Survey: A Study of Trial Participant Perspectives on Clinical Trial Management and Patient-Centric Management Practices.
    Peterson IS; Mazzella AJ; Belter LT; Curry MA; Cruz RE; Jarecki J
    Neurol Ther; 2022 Sep; 11(3):1167-1181. PubMed ID: 35635603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mixed method study on the impact of living with spinal muscular atrophy in Malaysia from patients' and caregivers' perspectives.
    Ch'ng GS; Koh K; Ahmad-Annuar A; Taib F; Koh CL; Lim ESC
    Orphanet J Rare Dis; 2022 May; 17(1):200. PubMed ID: 35578241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Filling the gaps in knowledge translation: Physical therapy recommendations for individuals with spinal muscular atrophy compared to standard of care guidelines.
    Trenkle J; Brugman J; Peterson A; Roback K; Krosschell KJ
    Neuromuscul Disord; 2021 May; 31(5):397-408. PubMed ID: 33741230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the relationship between the 32-item motor function measure and daily activities from an individual with spinal muscular atrophy and their caregivers' perspective: a two-part study.
    Duong T; Braid J; Staunton H; Barriere A; Petridis F; Reithinger J; Cruz R; Jarecki J; De Lemus M; Gusset N; Broekgaarden R; Randhawa S; Flynn J; Arbuckle R; Reif S; Yang L; De Martini A; Vuillerot C
    BMC Neurol; 2021 Mar; 21(1):143. PubMed ID: 33789607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "I have SMA, SMA doesn't have me": a qualitative snapshot into the challenges, successes, and quality of life of adolescents and young adults with SMA.
    Mazzella A; Curry M; Belter L; Cruz R; Jarecki J
    Orphanet J Rare Dis; 2021 Feb; 16(1):96. PubMed ID: 33618755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Barriers and facilitating factors of care coordination for children with spinal muscular atrophy type I and II from the caregivers' perspective: an interview study.
    Willems J; Bablok I; Farin-Glattacker E; Langer T
    Orphanet J Rare Dis; 2023 Jun; 18(1):136. PubMed ID: 37268965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spinal muscular atrophy care in the COVID-19 pandemic era.
    Veerapandiyan A; Connolly AM; Finkel RS; Arya K; Mathews KD; Smith EC; Castro D; Butterfield RJ; Parsons JA; Servais L; Kuntz N; Rao VK; Brandsema JF; Mercuri E; Ciafaloni E
    Muscle Nerve; 2020 Jul; 62(1):46-49. PubMed ID: 32329921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom.
    Lo SH; Gorni K; Sutherland CS; Martí Y; Lloyd A; Paracha N
    Pharmacoeconomics; 2022 Apr; 40(Suppl 1):91-102. PubMed ID: 34658007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life of children with spinal muscular atrophy and their caregivers from the perspective of caregivers: a Chinese cross-sectional study.
    Yao M; Ma Y; Qian R; Xia Y; Yuan C; Bai G; Mao S
    Orphanet J Rare Dis; 2021 Jan; 16(1):7. PubMed ID: 33407670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers.
    Sutherland CS; Hudson P; Mitchell S; Paracha N
    Pharmacoeconomics; 2022 Apr; 40(Suppl 1):39-67. PubMed ID: 34907515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parents as informal caregivers of children and adolescents with spinal muscular atrophy: a systematic review of quantitative and qualitative data on the psychosocial situation, caregiver burden, and family needs.
    Brandt M; Johannsen L; Inhestern L; Bergelt C
    Orphanet J Rare Dis; 2022 Jul; 17(1):274. PubMed ID: 35854387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Getting ready for the adult world": how adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being.
    Wan HWY; Carey KA; D'Silva A; Kasparian NA; Farrar MA
    Orphanet J Rare Dis; 2019 Apr; 14(1):74. PubMed ID: 30940178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review.
    Landfeldt E; Abner S; Pechmann A; Sejersen T; McMillan HJ; Lochmüller H; Kirschner J
    Pharmacoeconomics; 2023 Mar; 41(3):275-293. PubMed ID: 36515815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of experiential knowledge within attitudes towards genetic carrier screening: A comparison of people with and without experience of spinal muscular atrophy.
    Boardman FK; Young PJ; Warren O; Griffiths FE
    Health Expect; 2018 Feb; 21(1):201-211. PubMed ID: 28703871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries.
    Lo SH; Lawrence C; Martí Y; Café A; Lloyd AJ
    Pharmacoeconomics; 2022 Apr; 40(Suppl 1):103-115. PubMed ID: 34897574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.